JL, I totally agree with you. in fact in yesterday's conference, JT clearly mentioned that their base case scenario is for 2017 and should there be overwhelming results at the 60% interim expected during year 2016, a halt and stoppage of the trial is an option.
We had a same discussion one week ago, so I have to assume: - you do not want or could not understand what I am saying or - a post from HDGabor makes you see red and do not think before post
So, - nobody said it belongs to the FDA, BUT the SPA is in place - yes, "The company can do anything wants", but what a "surprise" they did not increase the TG enrollment criteria without SPA modification (-> FDA was involved) - nobody said "Amarin does to change the trial design". Any analysis AFTER full enrollment isn't a change of the design and could not affect it since ALL patients were enrolled at the time of the analysis
The protocol includes an analysis @100% and 60%. BOTH could produce meaningful data! Without full details: - final: eff. 15%, p =< 0.046 - 60% interim: app. 25-27%, p =< 0.0076
I do not see any reason, why additional interim analysis @80% or @50% (AFTER FULL ENROLLMENT) could not produce meaningful data. ie: - @80%: eff. 20%, p =< 0.025 - @50%: eff. 35%, p =< 0.005
All interim could provide a statistically meaningful and valid result.
To be more precise: the @50% will be a little bit higher and the more exact definition (independently from event number) is "interim after full enrollment)
Since time is money, both additional interim look (but again: if any) is could for Amarin (@"50" - 4 months earlier than @60 / in November, @80 - 11 months / halfway between @60 and @100)
I forgot to mention one thing (addition to #58998):
Meanwhile you are fine with an analysis based on guess / "ethical" reason (actual event# is less than expected) without protocol, you are saying that additional predefined look with protocol is dangerous / risky.